Global Blood Therapeutics, Inc. (NASDAQ:GBT) has been given a $53.00 price objective by Oppenheimer Holdings, Inc. in a research report issued on Monday. The brokerage currently has a “buy” rating on the stock. Oppenheimer Holdings, Inc.’s price objective indicates a potential upside of 64.85% from the stock’s current price.

A number of other research firms have also recently commented on GBT. Cowen and Company reaffirmed an “outperform” rating and set a $83.00 target price on shares of Global Blood Therapeutics in a research note on Monday, August 14th. Wedbush reaffirmed an “ourperform” rating and set a $73.00 target price on shares of Global Blood Therapeutics in a research note on Monday, September 18th. Morgan Stanley reaffirmed an “overweight” rating on shares of Global Blood Therapeutics in a research note on Tuesday, July 11th. BidaskClub raised Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Finally, Zacks Investment Research cut Global Blood Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Global Blood Therapeutics has an average rating of “Buy” and an average price target of $54.08.

Global Blood Therapeutics (NASDAQ GBT) traded down 1.23% during trading on Monday, reaching $32.15. The company had a trading volume of 1,824,015 shares. Global Blood Therapeutics has a one year low of $13.35 and a one year high of $41.15. The firm’s 50 day moving average is $29.99 and its 200 day moving average is $29.15. The company’s market capitalization is $1.40 billion.

Global Blood Therapeutics (NASDAQ:GBT) last released its earnings results on Monday, August 7th. The company reported ($0.55) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.06. During the same period in the prior year, the firm posted ($0.58) EPS. On average, equities research analysts predict that Global Blood Therapeutics will post ($2.44) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/23/global-blood-therapeutics-inc-gbt-pt-set-at-53-00-by-oppenheimer-holdings-inc.html.

In other Global Blood Therapeutics news, insider Jung Choi sold 3,000 shares of the company’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $30.00, for a total transaction of $90,000.00. Following the completion of the sale, the insider now owns 140,055 shares in the company, valued at $4,201,650. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Deval L. Patrick sold 27,053 shares of the company’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $29.69, for a total value of $803,203.57. Following the sale, the director now owns 12,053 shares of the company’s stock, valued at approximately $357,853.57. The disclosure for this sale can be found here. Insiders sold 36,053 shares of company stock valued at $1,081,154 in the last quarter. 5.30% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. Parametric Portfolio Associates LLC lifted its holdings in Global Blood Therapeutics by 0.9% during the second quarter. Parametric Portfolio Associates LLC now owns 30,943 shares of the company’s stock worth $846,000 after buying an additional 284 shares during the period. Legal & General Group Plc lifted its holdings in Global Blood Therapeutics by 10.1% during the first quarter. Legal & General Group Plc now owns 4,816 shares of the company’s stock worth $178,000 after buying an additional 440 shares during the period. American International Group Inc. lifted its holdings in Global Blood Therapeutics by 24.1% during the first quarter. American International Group Inc. now owns 10,031 shares of the company’s stock worth $370,000 after buying an additional 1,945 shares during the period. Alps Advisors Inc. lifted its holdings in Global Blood Therapeutics by 7.9% during the second quarter. Alps Advisors Inc. now owns 39,366 shares of the company’s stock worth $1,077,000 after buying an additional 2,874 shares during the period. Finally, Great West Life Assurance Co. Can purchased a new stake in Global Blood Therapeutics during the first quarter worth $129,000. Institutional investors own 86.07% of the company’s stock.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Analyst Recommendations for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.